Rafael Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $66.09M
- P/E (TTM)
- –
- Dividend yield
- –
About Rafael
Pharmaceutical Preparations, SIC 2834
Rafael Holdings, Inc. operates as a biotechnology enterprise focused on pharmaceutical development and equity investments in healthcare businesses. Its principal product candidate is Trappsol Cyclo, an investigational cyclodextrin drug evaluated for treating Niemann-Pick Disease Type C1. The company's subsidiaries also engage in liposome-based cancer treatments, oncology therapeutics, orthopedic instruments for minimally invasive surgery, and ingredient delivery technologies. Additionally, it sells cyclodextrin products to commercial clients in the pharmaceutical and nutritional sectors, serving healthcare providers, adult and pediatric patients with rare conditions, and industrial manufacturers.
The company's clinical activities include a global study authorized across more than 30 sites in 13 countries: the United States, the United Kingdom, Germany, Poland, Spain, Italy, Israel, Turkey, Saudi Arabia, Australia, Brazil, Argentina, and Taiwan. Outside its biopharmaceutical pipeline, the company holds a partial interest in a commercial building in Jerusalem, Israel. Corporate executive offices are located in Newark, New Jersey.
Summary of the business section of Rafael's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rafael Holdings, Inc.
- Headquarters
- Newark, NJ
- Address
- 520 Broad Street 07120
- Phone
- (212) 658-1450
- Website
- rafaelholdings.com
- Employees
- 23, Jul 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- July 31
- Auditor
- CohnReznick LLP, New York, New York
Stock & identifiers
- Ticker
- RFL
- Exchange
- NYSE
- Shares outstanding
- 52M, Jun 9, 2026
- Public float
- $38.60M, Jan 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1713863
- CUSIP
- 75062E106
- ISIN
- US75062E1064
- EIN
- 82-2296593
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Howard S. Jonas | Exec Chairman, CEO & President, Director | 15,042,108 |
| David Polinsky | Chief Financial Officer | 297,084 |
| Joshua M. Fine | Chief Operating Officer | 9,380 |
| William Conkling | Chief Executive Officer | 564,455 |
| John Goldberg | CHIEF MEDICAL OFFICER | 50,000 |
| Markus Sieger | Director | 219,710 |
| Mark N. Stein | Director | 50,845 |
| Michael J. Weiss | Director | 141,861 |
| Alan Grayson | Director | 6,562 |
| N. Scott Fine | Director | 335,348 |
| Stephen M. Greenberg | Director | 102,491 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Howard Jonas | $294.00K | $298.89K | $530.55K | $85 | – |
| FY2025 William Conkling | $592.91K | $611.63K | $530.55K | $85 | – |
| FY2024 William Conkling | $859.30K | $658.22K | $649.20K | $74 | – |
| FY2023 William Conkling | $751.95K | $685.32K | $406.69K | $99 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“our different businesses units is critical to our success. As of October 27, 2025, Rafael Holdings and its subsidiaries had 21 full-time and 2 part-time employees. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and i”
Corporate history
Events identified from SEC filings